![]() |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vol. 296, Issue 2, 345-350, February 2001
Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan
| |
Abstract |
|---|
|
|
|---|
Hypertension produced by chronic infusion of angiotensin II (Ang II) is
significantly blunted by blockade of endothelin-1 (ET-1)
ETA subtype receptors. Furthermore, this model is
salt-sensitive, and the antihypertensive response to ETA
receptor blockade is more pronounced in animals on high salt intake.
The goal of these experiments was to evaluate the effect of salt intake
and Ang II on vascular reactivity to ET-1. In superior mesenteric
arteries from normal male rats, studied in a standard muscle bath,
incubation for 1 h with a subcontractile concentration of Ang II
(10
10 M) did not affect concentration-response curves to
ET-1. Pressor responses in vivo to 2-h infusions of Ang II (5 ng/min)
in rats maintained on normal or high salt intake were abolished by
pretreatment with the ETA receptor antagonist ABT-627. The
antagonist had no effect on pressor responses to phenylephrine (PE). In
other experiments, rats maintained on either high or normal salt intake
received continuous infusion of Ang II (5 ng/min i.v.) for 7 days, and then their superior mesenteric arteries were tested in the muscle bath.
The maximum contractile response to ET-1 in arteries from Ang
II-infused rats on normal salt intake was larger than in arteries from
rats not receiving Ang II. Conversely, maximum responses to ET-1 in
arteries from Ang II-infused rats on high salt intake were depressed
compared with controls. No differences in vascular reactivity to PE
were found. Thus, chronic in vivo exposure to Ang II results in
specific salt-dependent changes in vascular reactivity to ET-1.
| |
Introduction |
|---|
|
|
|---|
Chronic
infusion of angiotensin II (Ang II) is an experimental model of
"salt-sensitive" hypertension, i.e., infusion rates of Ang II that
do not affect arterial pressure in animals on low or normal salt intake
cause a significant rise in pressure in animals on higher salt intakes
(Muirhead et al., 1975
; Kanagy et al., 1990
; Ando et al., 1991
; Csiky
and Simon, 1997
). The endothelial cell-derived vasoconstrictor peptide
endothelin-1 (ET-1) is now believed to play a key role in this and
several other salt-sensitive forms of hypertension (Schiffrin, 1999
).
Ang II has been shown to increase endothelial cell synthesis and
release of ET-1 both in vitro (Emori et al., 1991
; Dohi et al., 1992
;
Imai et al., 1992
; Kohno et al., 1992
) and in vivo (Barton et al.,
1997
; Moreau et al., 1997
; Lariviere et al., 1998
; Ferri et al., 1999
).
Ang II also potentiates the acute vascular contractile response to other agonists (Henrion et al., 1992
; Qui et al., 1994
; Dowell et al.,
1996
), although this has not been demonstrated with ET-1. Chronic Ang
II infusion, however, has been reported to potentiate pressor responses
to chronic ET-1 infusion (Yoshida et al., 1992
). Most importantly, the
development of hypertension in response to Ang II was attenuated by
concomitant treatment with ET-1 receptor antagonists (d'Uscio et al.,
1997
; Rajagopalan et al., 1997
; Herizi et al., 1998
). We hypothesized
that ET-1 could also participate in the salt sensitivity of Ang
II-induced hypertension, because administration of a selective
ETA receptor antagonist to rats with Ang
II-induced hypertension produced a larger and more sustained fall in
arterial pressure when animals were on high versus normal salt intake
(Ballew and Fink, 2000
). The goal of the current investigation was to
determine whether vascular reactivity to ET-1 is differentially affected by salt intake during chronic Ang II infusion.
| |
Materials and Methods |
|---|
|
|
|---|
Animals. All animal procedures were carried out in accordance with institutional guidelines established by Michigan State University. Male Sprague-Dawley rats weighing 350 to 450 g were purchased from Charles River Laboratories (Portage, MI). Upon arrival at our facility, rats were maintained according to standards approved by the Michigan State University All-University Committee on Animal Use and Care. All experimental procedures were carried out in accordance with the Guiding Principles in the Care and Use of Animals of the American Physiological Society. Rats were acclimatized for at least 2 days before surgical procedures in clear plastic boxes and were allowed access to standard rat chow (Teklad 22/5 Rodent Diet W 8640, Madison, WI) and tap water ad libitum.
Isolated Tissue Bath Protocol.
Rats were killed (80 mg/kg
pentobarbital i.p.) and the superior mesenteric arteries were dissected
into helical strips. The endothelium was left intact. Tissues were
placed in physiological salt solution containing 130 mmol/l NaCl, 4.7 mmol/l KCl, 1.18 mmol/l
KH2PO4, 1.17 mmol/l
MgSO4·7H2O, 1.6 mmol/l
CaCl2·2H2O, 14.9 mmol/l
NaHCO3, 5.5 mmol/l dextrose, and 0.03 mmol/l
CaNa-EDTA. One end of the preparation was attached to a glass rod and
the other to a force transducer (model FT03; Grass Instruments, Quincy, MA), and the strip was placed under optimum resting tension (600 mg, as
previously determined) and allowed to equilibrate for 1 h. Muscle
baths were filled with warmed (37°C), aerated (95%
O2, 5% CO2) physiological
salt solution. Changes in isometric force were recorded on a polygraph
(Grass Instruments). After the hour of equilibration, arteries were
challenged with a maximal concentration of the
1-adrenergic receptor agonist phenylephrine
(PE, 10 µmol/l). Tissues were then washed, and the status of the
endothelium was examined by observing arterial relaxation to the
endothelium-dependent agonist acetylcholine (1 µmol/l) in
tissues contracted by a half-maximal concentration of PE (~10
nmol/l).
9-10
5 M) followed
by ET-1 (10
11-10
7 M).
The tissues were incubated with each concentration for ~5 min before
the next concentration was added. In some preparations, superior
mesenteric arteries were incubated with Ang II
(10
10 M), A-192621 (an
ETB-selective receptor antagonist, 30 nM; Abbott Laboratories, Abbott Park, IL), ABT-627 (an
ETA-selective receptor antagonist, 30 nM; Abbott
Laboratories), or A-182086 (an ET
A/B-nonselective receptor antagonist, 30 nM;
Abbott Laboratories), for 1 h before the production of ET-1
dose-response curves.
In Vivo Protocol.
Normal male Sprague-Dawley rats were
chronically instrumented for direct, daily measurements of blood
pressure and heart rate via catheterization of the femoral artery and
vein, as previously described (Potter et al., 1997
). Rats were housed
in metabolism cages. Venous catheters were attached to a syringe pump
via a hydraulic swivel mounted above the cage. Sodium intake was fixed by delivering sodium chloride via continuous intravenous infusion (5.0 ml/day) to rats consuming a sodium-deficient diet (Teklad) and drinking
distilled water. Rats were maintained on either high salt (sodium
chloride) intake (n = 12, 6 mEq/day; 1.2 mEq/ml) or
normal salt intake (n = 10, 2 mEq/day; 0.4 mEq/ml) for
at least 3 days before, and throughout the remainder of, the
experiment. Systolic, diastolic, and mean arterial pressures and heart
rate were recorded via the femoral arterial catheter each morning of the protocol between 8:00 and 11:00 AM. The arterial catheters were
connected to low-volume displacement pressure transducers that were
first zeroed at the level of the rat's heart. The transducers were
connected to digital pressure monitors (Digi-Med blood pressure analyzer; Micro-Med, Louisville, KY) that output directly to a computerized digital pressure monitoring system. Data were collected once every second for 15 to 30 min. The daily value was the average of
the 1-s recordings taken over the last 5 min of the recording session.
Data Analysis. Estimates of maximum response and EC50 values were obtained from each concentration response curve using a four-parameter logistic function. Results are expressed as mean ± S.E.M. For these results, mean values were compared statistically using a one-way ANOVA followed by the protected least significant difference test for post hoc comparisons. For in vivo data, within- and between-group differences were analyzed using mixed-design ANOVA. Post hoc comparisons between groups were performed by testing for simple main effects. Within group comparisons were made using the protected least significant difference test. Criterion for statistical significance was a probability level of less than 0.05.
| |
Results |
|---|
|
|
|---|
To confirm that contraction of superior mesenteric arteries to
ET-1 is mediated exclusively by ETA receptors, we
tested the ability of three different ET-1 receptor antagonists to
block contractions to ET-1 (Fig. 1). With A-192621, an
ETB-selective receptor antagonist, there were no
differences in EC50 or maximal response compared
with untreated arteries (control: 1.5 ± 0.3 × 10
9 M and 133.3 ± 11%; A-192621:
1.2 ± 0.3 × 10
9 M and 128 ±11%).
With A-182086, an ETA/B receptor antagonist, there were no differences in maximal response compared with untreated arteries (control: 133.3 ± 11%; A-182086: 148 ± 10%).
However, the EC50 value was significantly
increased (control: 1.5 ± 0.3 × 10
9
M; A-182086: 6.5 ± 0.7 × 10
9 M).
Curve parameters could not be determined for ABT-627 because the curve
was extremely right-shifted.
To test the possibility that Ang II rapidly augments vascular
reactivity to ET-1, an ET-1 concentration-response curve was generated
in vessels preincubated for 1 h with a subcontractile concentration of Ang II (10
10 M). As shown in
Fig. 2, the maximal response to ET-1 in
animals exposed to subcontractile levels of Ang II (132.4 ± 17.8% PE contraction) was not significantly different from the maximal
response in control rats (155.5 ± 12.6% PE contraction).
There was no difference in EC50 values between
the two groups.
|
To determine whether pressor responses during short-term exposure to
Ang II in rats on high or normal salt intake is influenced by
endogenous levels of ET-1 acting on ETA
receptors, Ang II (5 ng/min, n = 5) and PE (2 µg/min,
n = 5) were infused into conscious rats. Mean arterial
pressure (MAP) was similarly and significantly increased in both normal
and high salt groups after 2 h of infusion either of Ang II or PE
(Fig. 3). One day later, this protocol was repeated in the same rats 1 h after administration of the selective ETA receptor antagonist ABT-627 (2 mg/kg). Treatment with ABT-627 alone did not significantly change MAP.
Two hours following the start of Ang II infusion in rats exposed to
ABT-627, there was no significant increase in MAP (Fig. 3). PE-infused rats showed a significant increase in MAP that was similar in magnitude
to that observed in the absence of ABT-627 treatment.
|
Chronic infusion of Ang II produced a significant elevation of MAP
compared with that seen in control rats regardless of salt intake
(Table 1). This increase was
significantly (p = 0.0329) larger in animals on high
salt intake than in those on normal salt intake. As shown in Fig.
4, maximal responses of rat superior mesenteric arteries to PE in Ang II-infused rats on normal (132.6 ± 16.9% PE contraction) and high salt intake (90.6 ± 11.5% PE contraction) were not significantly different from each other or their
respective controls (100.9 ± 9.4 and 134.7 ± 27.6% PE contraction). There were no significant differences in the
EC50 values between the four groups in response
to PE.
|
|
As shown in Fig. 4, superior mesenteric arteries from Ang II-infused rats on normal salt intake had significantly increased maximum responses to ET-1 (251.8 ± 28.6% PE contraction) compared with controls (135.3 ± 31.9% PE contraction; p = 0.0495). Conversely, superior mesenteric arteries from Ang II-infused rats on high salt intake had significantly decreased maximum response to ET-1 (123.4 ± 35.4% PE contraction) compared with controls (245.6 ± 41.7% PE contraction; p = 0.0263). There was no significant difference in maximal contraction to ET-1 between high salt and normal salt control groups (p = 0.141). There were no significant differences in the EC50 values between the four groups in response to ET-1.
| |
Discussion |
|---|
|
|
|---|
The overall goal of our research is to define the mechanisms
responsible for the salt sensitivity of Ang II-induced hypertension. We
recently demonstrated that blockade of ETA
receptors in rats receiving chronic intravenous infusions of Ang II
causes a larger and more sustained fall in arterial pressure when the
rats were on a high versus a normal salt intake (Ballew and Fink,
2000
). This result led us to conclude that ET-1 could participate in the mechanism of salt sensitivity in Ang II-induced hypertension. The
goal of the current studies was to test the hypothesis that the
salt-sensitivity of Ang II-induced hypertension is due in part to
amplification of the vascular contractile effects of ET-1. The main new
finding from this work is that chronic infusion of Ang II alters
mesenteric vascular reactivity to ET-1 in a salt-dependent manner: in
rats on normal salt intake maximum contractile responses to ET-1 are
increased, whereas in rats on high salt intake they are decreased. If
these changes also occur in other major vascular beds, such as skeletal
muscle and kidney, they could exert an important effect on arterial
pressure regulation.
In vitro studies show that short-term exposure (30-60 min)
to very low (subthreshold for direct contraction) concentrations of Ang
II potentiates vascular contractile responses to other agonists
(Henrion et al., 1992a
). The mechanism of this effect is not fully
elucidated, but probably involves activation of protein kinase C in the
vascular smooth muscle cell (Henrion et al., 1992b
). This action of Ang
II has not been tested with ET-1 as the second agonist, but the strong
similarity in signaling mechanisms used by Ang II and ET-1 in vascular
smooth muscle (Tsuda et al., 1993
) makes it a likely possibility.
Furthermore, there is evidence from chronic (6-day) in vivo experiments
in rats that the pressor actions of ET-1 are potentiated by concomitant
exposure to Ang II (Yoshida et al., 1992
). Another study though failed
to find such an effect during rapid, bolus injections of the two
agonists in the canine coronary circulation (Kiss et al., 1998
). Our
data do not support the idea that contractile effects of ET-1 are
amplified after short-term exposure to Ang II in vitro, at least in the superior mesenteric artery of the rat. We observed no significant change in the concentration-response curve to ET-1 in arteries pre-exposed for 1 h to Ang II.
Pressor responses, and changes in hindlimb vascular
resistance, to acute bolus injections of Ang II in vivo are reported to be reduced by prior blockade of ET-1 receptors, especially when low
doses of Ang II are administered (Balakrishnan et al., 1996
; Champion
et al., 1998
). This suggests that physiological amounts of ET-1 may
amplify the vascular contractile response to Ang II in vivo. We
performed experiments to investigate this phenomenon in rats on normal
and high salt intake. Our results confirm that pressor responses to
acute (2-h) exposure to low amounts of Ang II in vivo are significantly
reduced by prior blockade of ETA receptors. This
effect appears to be specific for Ang II since no change in the pressor
response to phenylephrine infusion was seen after administration of the
ETA antagonist. One interpretation of these
results is that Ang II infusion for 2 h stimulated the release of
ET-1 from arterial endothelial cells, and that this ET-1 accounted of
the accompanying rise in arterial pressure. Most studies, however, have
failed to find evidence for ET-1 release by Ang II in short-term
infusion protocols (Klein et al., 1995
; Delemarre et al., 1998
),
including an investigation in humans on differing levels of salt intake
(Ferri et al., 1999
). Thus, we interpret the results to indicate that
physiological amounts of ET-1 acting at ETA
receptors amplify the pressor actions of exogenous Ang II. Our data,
however, do not provide any insight into the mechanism of this
interaction. It is notable though that this short-term effect was
observed in rats on both normal and high salt intake, and therefore is
not likely to alone explain the salt-sensitivity of chronic Ang
II-induced hypertension.
In a final experiment, we evaluated vascular reactivity to
ET-1 in vitro in superior mesenteric arteries from rats made
hypertensive with Ang II. We found divergent results depending on
whether the rats were on normal or high salt intake. Rats on high salt
intake became significantly more hypertensive than rats on normal salt intake. Furthermore, maximal response of mesenteric arteries to ET-1
from these rats was significantly suppressed compared with responses in
control rats on high salt intake. Similar results have been reported by
other investigators using a model of chronic Ang II-induced
hypertension involving infusion of higher doses of Ang II (200 ng/kg/min, subcutaneously) in rats on normal salt intake (d'Uscio et
al., 1997
; Rajagopalan et al., 1997
). Arteries from those rats
exhibited a marked increase in preproET-1 gene expression and ET-1
peptide content (Rajagopalan et al., 1997
; d'Uscio et al., 1998
), and
there was a strong negative correlation between reactivity to ET-1 and
arterial peptide concentrations (d'Uscio et al., 1998
). It has been
suggested that a decrease in mesenteric response to ET-1 in vitro is a
consequence of ETA receptor down-regulation
caused by chronic increase in ET-1 release (Nguyen et al., 1992
).
Although we did not measure arterial content of ET-1 in our studies, we
propose that a similar mechanism could account for depressed maximal
responses to ET-1 in superior mesenteric arteries from rats in our
study on high salt intake and Ang II infusion.
Mesenteric arteries from rats receiving Ang II but normal salt intake
exhibited a significantly increased maximum response to ET-1 in vitro.
This is the first report of potentiation by exogenous Ang II of in
vitro contractile responses to ET-1 in vascular smooth muscle, although
others have reported that Ang II amplifies the bronchoconstrictor
actions of ET-1 via a leukotriene-dependent pathway (Pitt and Nally,
1999
). Contraction of superior mesenteric arteries to ET-1 is mediated
exclusively through ETA receptors (Fig.
1), and Ang II has been reported to increase
ETA receptor expression (Hatakeyama et al.,
1994
). Thus, one potential explanation for our results is that chronic
exposure to Ang II increased ETA receptor number
in superior mesenteric arteries in rats on normal salt intake.
|
This does not explain, however, why the effects of Ang II
infusion on arterial contraction to ET-1 in vitro were different in
rats on high versus normal salt intake. Our experiments do not provide
a definitive answer. We speculate that long-term exposure to Ang II can
up-regulate both ETA receptor number and
preproET-1 gene expression. Although high salt intake alone does not
stimulate vascular ET-1 formation (Ikeda et al., 1999
), our data are
consistent with the idea that high salt intake plus Ang II may be a
more effective stimulus to preproET-1 gene expression and ET-1
synthesis than Ang II alone. One possible mechanism could involve the
effects of Ang II and high salt intake on endothelial nitric oxide (NO) action. Long-term exposure to Ang II in vivo (d'Uscio et al., 1997
),
and to high salt intake (Boegehold, 1995
), are reported to impair NO
activity in resistance arteries. There is also evidence that increased
NO activity suppresses ET-1 formation in blood vessels (Boulanger and
Lüscher, 1990
). The combination of Ang II and high salt could
produce a larger increase in vascular ET-1 synthesis than Ang II alone
because of less NO-mediated inhibition. In support of this idea, we
showed that administration of the NO synthase inhibitor
L-nitro-arginine methyl ester, to rats on normal salt
intake caused a highly significant potentiation of the chronic pressor
responses to Ang II infusion in rats (Melaragno and Fink, 1996
).
Finally, there is evidence that the pressor (Mortensen and Fink, 1992
)
and vascular resistance (Grossman et al., 1990
) effects of ET-1 are
increased by high salt intake. Therefore, enhanced synthesis of ET-1 in
blood vessels in rats on high salt intake receiving Ang II, combined
with some amplification of the pressor effect of ET-1 by high salt
alone, could explain the larger contribution of ET-1 to Ang II-induced
hypertension under high salt conditions. Direct evidence for this
theory needs to be obtained in future experiments.
In summary, Ang II was shown to cause changes in pressor and mesenteric
vascular contractile effects of ET-1 that are dependent on time of
exposure to Ang II, and on salt intake. During long-term infusion Ang
II can increase both mesenteric vascular reactivity to ET-1 (this
study) and ET-1 formation (Barton et al., 1997
; Moreau et al., 1997
;
Lariviere et al., 1998
). Each of these mechanisms may contribute to the
dependence of Ang II-induced hypertension on ETA
receptor activation, but high salt intake apparently shifts the balance
toward the latter.
| |
Acknowledgments |
|---|
We thank Barbara Grant for excellent technical assistance. ABT-627, A-192621, and A-182086 were a generous gift of Abbott Laboratories.
| |
Footnotes |
|---|
Accepted for publication October 30, 2000.
Received for publication August 8, 2000.
This work was supported by National Heart, Lung, and Blood Institute Grant HL42111.
Send reprint requests to: Gregory D. Fink, Ph.D., B-327 Life Science Bldg., Michigan State University, East Lansing, MI 48824. E-mail: finkg{at}msu.edu
| |
Abbreviations |
|---|
Ang II, angiotensin II; ET-1, endothelin-1; PE, phenylephrine; MAP, mean arterial pressure; NO, nitric oxide.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
T. Matsumoto, K. Ishida, N. Nakayama, T. Kobayashi, and K. Kamata Involvement of NO and MEK/ERK pathway in enhancement of endothelin-1-induced mesenteric artery contraction in later-stage type 2 diabetic Goto-Kakizaki rat Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1388 - H1397. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Kunert, M. R. Dwinell, I. Drenjancevic Peric, and J. H. Lombard Sex-specific differences in chromosome-dependent regulation of vascular reactivity in female consomic rat strains from a SS x BN cross Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2008; 295(2): R516 - R527. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Allahdadi, T. W. Cherng, H. Pai, A. Q. Silva, B. R. Walker, L. D. Nelin, and N. L. Kanagy Endothelin type A receptor antagonist normalizes blood pressure in rats exposed to eucapnic intermittent hypoxia Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H434 - H440. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Schneider, E. W. Inscho, and D. M. Pollock Attenuated vasoconstrictor responses to endothelin in afferent arterioles during a high-salt diet Am J Physiol Renal Physiol, April 1, 2007; 292(4): F1208 - F1214. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. P. del Villar, C. J. G. Alonso, C. A. Feldstein, L. A. Juncos, and J. C. Romero Role of Endothelin in the Pathogenesis of Hypertension Mayo Clin. Proc., January 1, 2005; 80(1): 84 - 96. [Abstract] [PDF] |
||||
![]() |
A. Montanari, A. Biggi, N. Carra, M. Ziliotti, E. Fasoli, L. Musiari, P. Perinotto, and A. Novarini Endothelin-A Receptors Mediate Renal Hemodynamic Effects of Exogenous Angiotensin II in Humans Hypertension, October 1, 2003; 42(4): 825 - 830. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||